Ultragenyx Pharmaceutical - RARE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $91.18
  • Forecasted Upside: 72.86%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$52.75
▼ -0.91 (-1.70%)

This chart shows the closing price for RARE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ultragenyx Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RARE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RARE

Analyst Price Target is $91.18
▲ +72.86% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $91.18, with a high forecast of $133.00 and a low forecast of $48.00. The average price target represents a 72.86% upside from the last price of $52.75.

This chart shows the closing price for RARE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in Ultragenyx Pharmaceutical. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/27/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$84.00 ➝ $88.00Low
2/27/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$107.00Low
2/21/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$110.00 ➝ $111.00Low
2/16/2024WedbushBoost TargetNeutral ➝ Neutral$47.00 ➝ $48.00Low
2/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$114.00Low
1/30/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$57.00 ➝ $68.00Low
1/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$114.00Low
12/8/2023Wells Fargo & CompanyInitiated CoverageOverweight$72.00Low
11/3/2023Morgan StanleyLower TargetOverweight ➝ Overweight$90.00 ➝ $84.00Low
10/25/2023Piper SandlerLower TargetOverweight ➝ Overweight$135.00 ➝ $130.00Low
10/10/2023Morgan StanleyLower TargetOverweight ➝ Overweight$95.00 ➝ $90.00Low
9/25/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$114.00Low
8/4/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$95.00Low
8/4/2023WedbushLower Target$49.00 ➝ $47.00Low
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$82.00Low
6/7/2023CitigroupBoost Target$130.00 ➝ $133.00Low
6/6/2023Evercore ISIUpgradeIn-Line ➝ Outperform$60.00 ➝ $80.00Low
4/26/2023Cantor FitzgeraldInitiated CoverageOverweight$114.00Low
3/17/2023CitigroupLower Target$135.00 ➝ $130.00Low
2/17/2023Credit Suisse GroupReiterated RatingOutperform$96.00Low
2/17/2023Robert W. BairdBoost TargetOutperform$50.00 ➝ $57.00Low
2/3/2023Morgan StanleyLower TargetOverweight$100.00 ➝ $95.00Low
1/18/2023Canaccord Genuity GroupReiterated RatingBuy$90.00Low
12/30/2022HC WainwrightReiterated RatingBuy$82.00Low
11/4/2022The Goldman Sachs GroupLower TargetNeutral$74.00 ➝ $55.00Low
11/3/2022SVB LeerinkLower TargetOutperform$115.00 ➝ $108.00Low
11/3/2022Morgan StanleyLower TargetOverweight$109.00 ➝ $100.00Low
11/3/2022CowenLower Target$86.00 ➝ $65.00Low
11/3/2022Robert W. BairdUpgradeNeutral ➝ Outperform$63.00 ➝ $50.00Low
11/3/2022CowenLower Target$86.00 ➝ $65.00Low
11/3/2022Credit Suisse GroupLower TargetOutperform$105.00 ➝ $96.00Low
10/13/2022WedbushReiterated RatingNeutralLow
10/13/2022GuggenheimUpgradeNeutral ➝ Buy$50.00Low
8/9/2022Evercore ISILower Target$60.00Low
8/3/2022CitigroupLower Target$146.00 ➝ $142.00Low
7/29/2022BarclaysLower Target$141.00 ➝ $105.00Low
7/28/2022Piper SandlerLower TargetOverweight$135.00 ➝ $130.00Low
7/1/2022Stifel NicolausLower TargetBuy$176.00 ➝ $142.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$139.00 ➝ $101.00Low
5/18/2022Piper SandlerLower TargetOverweight$170.00 ➝ $135.00Medium
5/6/2022CowenLower Target$124.00 ➝ $99.00High
5/6/2022CowenLower Target$124.00 ➝ $99.00High
3/16/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform$99.00 ➝ $105.00High
2/11/2022Morgan StanleyLower TargetOverweight$120.00 ➝ $118.00High
2/11/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$132.00Low
2/1/2022Morgan StanleyLower TargetOverweight$156.00 ➝ $120.00High
10/5/2021SVB LeerinkReiterated RatingBuyMedium
9/30/2021HC WainwrightInitiated CoverageBuy$106.00High
8/19/2021UBS GroupInitiated CoverageSell$73.00Medium
8/3/2021WedbushLower TargetNeutral$106.00 ➝ $91.00High
8/3/2021BarclaysLower TargetOverweight$178.00 ➝ $141.00High
7/15/2021GuggenheimInitiated CoverageNeutral$84.74Low
6/29/2021Bank of AmericaUpgradeNeutral ➝ Buy$162.00High
5/9/2021SVB LeerinkInitiated CoverageBuy$178.00High
5/6/2021CitigroupUpgradeNeutral ➝ Buy$160.00 ➝ $151.00High
5/5/2021Evercore ISIUpgradeIn-Line ➝ Outperform$144.00High
5/5/2021Morgan StanleyLower TargetOverweight$170.00 ➝ $156.00Low
4/19/2021Morgan StanleyLower TargetOverweight$175.00 ➝ $170.00Medium
3/1/2021Stifel NicolausInitiated CoverageBuy$179.00High
2/16/2021SVB LeerinkBoost TargetOutperform$115.00 ➝ $178.00Low
2/12/2021WedbushBoost TargetNeutral$113.00 ➝ $130.00Low
2/12/2021Piper SandlerBoost TargetOverweight$165.00 ➝ $170.00Low
2/12/2021BarclaysBoost TargetOverweight$176.00 ➝ $186.00Low
2/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$165.00Low
1/25/2021Credit Suisse GroupBoost TargetNeutral$64.00 ➝ $99.00High
1/11/2021Robert W. BairdBoost TargetOutperform$110.00 ➝ $165.00Medium
1/11/2021BarclaysBoost TargetOverweight$121.00 ➝ $176.00High
12/7/2020WedbushDowngradeOutperform ➝ Neutral$105.00 ➝ $110.00Medium
11/24/2020Evercore ISIReiterated RatingIn-Line$110.00High
11/12/2020Bank of AmericaDowngradeBuy ➝ Neutral$104.00 ➝ $126.00High
10/28/2020Truist FinancialBoost Target$88.00 ➝ $110.00High
10/28/2020WedbushBoost TargetOutperform$97.00 ➝ $105.00Low
10/28/2020Morgan StanleyBoost TargetOverweight$89.00 ➝ $91.00Low
10/28/2020BarclaysBoost TargetOverweight$99.00 ➝ $121.00Medium
10/28/2020SVB LeerinkBoost TargetOutperform$110.00 ➝ $115.00Medium
10/27/2020Piper SandlerBoost TargetOverweight$83.00 ➝ $108.00Medium
10/15/2020Bank of AmericaBoost TargetBuy$93.00 ➝ $107.00Medium
10/13/2020Morgan StanleyBoost TargetOverweight$87.00 ➝ $89.00Medium
7/31/2020Credit Suisse GroupReiterated RatingHold$64.00Low
7/31/2020Morgan StanleyLower TargetOverweight$88.00 ➝ $87.00High
7/31/2020BarclaysBoost TargetOverweight$87.00 ➝ $99.00Low
7/28/2020JPMorgan Chase & Co.Reiterated RatingBuy$84.00High
7/15/2020Morgan StanleyBoost TargetOverweight$83.00 ➝ $88.00Low
7/1/2020SunTrust BanksBoost Target$82.00 ➝ $88.00Medium
7/1/2020Credit Suisse GroupBoost TargetNeutral$60.00 ➝ $64.00High
7/1/2020JPMorgan Chase & Co.Boost TargetOverweight$76.00 ➝ $84.00High
7/1/2020WedbushBoost TargetHold ➝ Outperform$83.00 ➝ $91.00High
7/1/2020Morgan StanleyBoost TargetOverweight$79.00 ➝ $83.00High
7/1/2020Robert W. BairdBoost TargetOutperform$75.00 ➝ $90.00High
6/30/2020Piper SandlerBoost TargetOverweight$70.00 ➝ $83.00High
6/19/2020SunTrust BanksBoost TargetBuy$80.00 ➝ $82.00High
6/19/2020WedbushBoost TargetOutperform$73.00 ➝ $83.00High
5/18/2020Stifel NicolausBoost TargetPositive ➝ Buy$70.00 ➝ $82.00High
5/8/2020CitigroupBoost TargetNeutral$53.00 ➝ $66.00Low
4/1/2020Robert W. BairdReiterated RatingBuy$75.00High
2/18/2020Evercore ISIReiterated RatingBuyLow
2/16/2020JPMorgan Chase & Co.Reiterated RatingBuy$76.00Low
2/14/2020WedbushBoost TargetOutperform$71.00 ➝ $75.00High
2/14/2020CowenReiterated RatingBuy$75.00High
1/17/2020Morgan StanleyBoost TargetOverweight$73.00 ➝ $77.00Low
1/10/2020SunTrust BanksReiterated RatingBuy$75.00 ➝ $80.00High
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
12/18/2019Piper Sandler CompaniesReiterated RatingBuy$70.00High
12/18/2019CowenReiterated RatingBuy$59.00High
12/17/2019Morgan StanleyLower TargetOverweight$76.00 ➝ $73.00Medium
11/6/2019Morgan StanleyLower TargetOverweight$79.00 ➝ $76.00High
11/6/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00High
11/5/2019CowenReiterated RatingBuy$62.00High
9/4/2019Piper Sandler CompaniesSet TargetBuy$75.00Low
9/4/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
9/4/2019SVB LeerinkReiterated RatingOutperform ➝ Positive$80.00 ➝ $85.00High
8/15/2019WedbushReiterated RatingBuy$75.00High
8/15/2019CowenReiterated RatingBuyHigh
8/5/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Medium
8/4/2019BarclaysReiterated RatingBuy$87.00Medium
8/2/2019Morgan StanleyLower TargetOverweight$83.00 ➝ $79.00High
8/2/2019WedbushReiterated RatingOutperform ➝ Outperform$75.00High
6/17/2019Morgan StanleySet TargetBuy$83.00Low
5/9/2019BarclaysReiterated RatingBuyLow
5/7/2019WedbushReiterated RatingOutperform$88.00 ➝ $77.00High
3/27/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$68.00 ➝ $83.00Medium
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2023
  • 10 very positive mentions
  • 6 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
9/1/2023
  • 7 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/1/2023
  • 8 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/31/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/30/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/30/2023
  • 15 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 21 very positive mentions
  • 20 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
2/28/2024

Current Sentiment

  • 21 very positive mentions
  • 20 positive mentions
  • 7 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Read More

Today's Range

Now: $52.75
Low: $52.58
High: $54.48

50 Day Range

MA: $46.68
Low: $43.02
High: $53.66

52 Week Range

Now: $52.75
Low: $31.52
High: $54.98

Volume

924,092 shs

Average Volume

789,559 shs

Market Capitalization

$4.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?

The following equities research analysts have issued reports on Ultragenyx Pharmaceutical in the last twelve months: Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, StockNews.com, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for RARE.

What is the current price target for Ultragenyx Pharmaceutical?

11 Wall Street analysts have set twelve-month price targets for Ultragenyx Pharmaceutical in the last year. Their average twelve-month price target is $91.18, suggesting a possible upside of 72.4%. Citigroup Inc. has the highest price target set, predicting RARE will reach $133.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $48.00 for Ultragenyx Pharmaceutical in the next year.
View the latest price targets for RARE.

What is the current consensus analyst rating for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RARE.

What other companies compete with Ultragenyx Pharmaceutical?

How do I contact Ultragenyx Pharmaceutical's investor relations team?

Ultragenyx Pharmaceutical's physical mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company's listed phone number is (415) 483-8800 and its investor relations email address is [email protected]. The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. Learn More about contacing Ultragenyx Pharmaceutical investor relations.